TIAA CREF Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 97.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 485,336 shares of the biopharmaceutical company’s stock after acquiring an additional 239,937 shares during the quarter. TIAA CREF Investment Management LLC owned 0.46% of Regeneron Pharmaceuticals worth $238,368,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in REGN. Gabelli Funds LLC boosted its holdings in Regeneron Pharmaceuticals by 13.3% during the 1st quarter. Gabelli Funds LLC now owns 6,800 shares of the biopharmaceutical company’s stock valued at $2,635,000 after acquiring an additional 800 shares during the period. Karp Capital Management Corp acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $7,524,000. Sei Investments Co. raised its position in Regeneron Pharmaceuticals by 4.0% in the 1st quarter. Sei Investments Co. now owns 246,601 shares of the biopharmaceutical company’s stock valued at $95,562,000 after purchasing an additional 9,426 shares in the last quarter. YorkBridge Wealth Partners LLC raised its position in Regeneron Pharmaceuticals by 42.0% in the 1st quarter. YorkBridge Wealth Partners LLC now owns 2,697 shares of the biopharmaceutical company’s stock valued at $1,084,000 after purchasing an additional 798 shares in the last quarter. Finally, Engineers Gate Manager LP raised its position in Regeneron Pharmaceuticals by 7.5% in the 1st quarter. Engineers Gate Manager LP now owns 2,850 shares of the biopharmaceutical company’s stock valued at $1,104,000 after purchasing an additional 200 shares in the last quarter. Institutional investors own 67.96% of the company’s stock.

REGN has been the topic of a number of analyst reports. Canaccord Genuity set a $484.00 price target on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, June 20th. BTIG Research reaffirmed a “buy” rating and issued a $540.00 price target (up previously from $480.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, June 30th. BidaskClub lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 6th. Bank of America Corporation reaffirmed a “buy” rating and issued a $593.00 price target (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Finally, Citigroup Inc. increased their price target on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a “buy” rating in a research report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $496.35.

COPYRIGHT VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by TIAA CREF Investment Management LLC” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/13/regeneron-pharmaceuticals-inc-regn-shares-bought-by-tiaa-cref-investment-management-llc.html.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded down 0.44% on Wednesday, hitting $442.51. The company’s stock had a trading volume of 124,539 shares. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The company has a 50 day moving average of $481.42 and a 200 day moving average of $444.42. The firm has a market cap of $46.92 billion, a PE ratio of 44.39 and a beta of 1.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business’s quarterly revenue was up 21.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.82 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.90 EPS for the current year.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi acquired 166,415 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was acquired at an average cost of $480.93 per share, with a total value of $80,033,965.95. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total value of $1,208,060.98. Following the completion of the transaction, the senior vice president now directly owns 9,193 shares of the company’s stock, valued at $4,894,537.06. The disclosure for this sale can be found here. Insiders have sold a total of 129,257 shares of company stock worth $61,745,394 over the last quarter. Insiders own 10.40% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.